Research programme: protein-targeted therapeutics - Quorex/Biogen IDEC

Drug Profile

Research programme: protein-targeted therapeutics - Quorex/Biogen IDEC

Alternative Names: Protein-targeted therapeutics research programme

Latest Information Update: 23 Mar 2007

Price : $50

At a glance

  • Originator Biogen Idec; Quorex Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Mar 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
  • 05 Sep 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top